Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
14 participants
INTERVENTIONAL
2021-02-03
2021-12-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
NCT06436911
A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine
NCT05685953
Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult
NCT02553837
A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination
NCT01963338
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
NCT05364242
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JNJ-64300535
Participants will receive an electroporation-mediated intramuscular (IM) injection of JNJ-64300535 vaccine.
JNJ-64300535
JNJ-64300535 injection will be administered intramuscularly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JNJ-64300535
JNJ-64300535 injection will be administered intramuscularly.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to adhere to the prohibitions and restrictions specified in this protocol
* Must be healthy as confirmed by medical history, physical examination, and vital signs performed at screening
Exclusion Criteria
* History of Human Immunodeficiency Virus (HIV) infection or a positive HIV antibody test at screening
* History of HBV infection, measured by the presence of HBsAg and/or anti-HBc antibodies
* History of seizure disorders unless seizure free for \>5 years
* Has a non-removable active electronic stimulation device
18 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Research & Development, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Research & Development, LLC Clinical Trial
Role: STUDY_DIRECTOR
Janssen Research & Development, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SGS Belgium NV
Edegem, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-005277-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
64300535HPB1003
Identifier Type: OTHER
Identifier Source: secondary_id
CR108950
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.